Sutro Biopharma (STRO) Net Income towards Common Stockholders Growth (1y) (2018 - 2025)

Sutro Biopharma (STRO) Net Income towards Common Stockholders Growth (1y) (2018 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 18.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 92.37%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Sutro Biopharma 204.80 Mn 63.37 Mn - 35.46%

Historic Data

Download Data
DateValue
Dec 31, 2025 35.46%
Sep 30, 2025 -16.54%
Jun 30, 2025 76.05%
Mar 31, 2025 -16.17%
Dec 31, 2024 -333.26%
Sep 30, 2024 1.01%
Jun 30, 2024 -24.64%
Mar 31, 2024 -16.31%
Dec 31, 2023 189.78%
Sep 30, 2023 -152.89%
Jun 30, 2023 -48.10%
Mar 31, 2023 -27.97%
Dec 31, 2022 9.26%
Sep 30, 2022 36.94%
Jun 30, 2022 -322.82%
Mar 31, 2022 -98.83%
Dec 31, 2021 -47.83%
Sep 30, 2021 37.47%
Jun 30, 2021 67.60%
Mar 31, 2021 -0.38%